share_log

Panbela Therapeutics | 8-K: Current report

Panbela Therapeutics | 8-K: Current report

Panbela Therapeutics | 8-K：重大事件
美股sec公告 ·  05/29 07:38
Moomoo AI 已提取核心訊息
Panbela Therapeutics, Inc. held a special meeting of stockholders on May 28, 2024, where two key proposals were voted upon. The first proposal, which was to effect a reverse stock split of the company's common stock at a ratio between 1-for-10 and 1-for-45, was approved by stockholders with 47,410,136 votes for, 44,904,765 against, and 28,979 abstentions. The second proposal, concerning the adjournment of the special meeting to solicit additional proxies if necessary, was also approved. However, the adjournment was deemed unnecessary as a quorum was present and the reverse stock split proposal passed. The Board of Directors has yet to determine the specific timing or ratio for the reverse stock split. The meeting's outcomes were filed in a Form 8-K report with the Securities and Exchange Commission on May 29, 2024, by Susan Horvath of Panbela Therapeutics.
Panbela Therapeutics, Inc. held a special meeting of stockholders on May 28, 2024, where two key proposals were voted upon. The first proposal, which was to effect a reverse stock split of the company's common stock at a ratio between 1-for-10 and 1-for-45, was approved by stockholders with 47,410,136 votes for, 44,904,765 against, and 28,979 abstentions. The second proposal, concerning the adjournment of the special meeting to solicit additional proxies if necessary, was also approved. However, the adjournment was deemed unnecessary as a quorum was present and the reverse stock split proposal passed. The Board of Directors has yet to determine the specific timing or ratio for the reverse stock split. The meeting's outcomes were filed in a Form 8-K report with the Securities and Exchange Commission on May 29, 2024, by Susan Horvath of Panbela Therapeutics.
Panbela Therapeutics, Inc. 於2024年5月28日舉行了股東特別會議，會上對兩項關鍵提案進行了表決。第一項提案是以1比10和1比45的比例對公司的普通股進行反向分割，該提案以47,410,136張贊成票、44,904,765票反對和28,979張棄權票獲得股東的批准。第二項提案也獲得批准，該提案涉及在必要時暫停特別會議，以徵集更多代理人。但是，由於存在法定人數，而且反向股票拆分提案獲得通過，因此休會被認爲沒有必要。董事會尚未確定反向股票拆分的具體時間或比例。會議結果由Panbela Therapeutics的蘇珊·霍瓦斯於2024年5月29日以8-K表格形式提交給美國證券交易委員會。
Panbela Therapeutics, Inc. 於2024年5月28日舉行了股東特別會議，會上對兩項關鍵提案進行了表決。第一項提案是以1比10和1比45的比例對公司的普通股進行反向分割，該提案以47,410,136張贊成票、44,904,765票反對和28,979張棄權票獲得股東的批准。第二項提案也獲得批准，該提案涉及在必要時暫停特別會議，以徵集更多代理人。但是，由於存在法定人數，而且反向股票拆分提案獲得通過，因此休會被認爲沒有必要。董事會尚未確定反向股票拆分的具體時間或比例。會議結果由Panbela Therapeutics的蘇珊·霍瓦斯於2024年5月29日以8-K表格形式提交給美國證券交易委員會。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息